Gastrointestinal Health News and Research

Latest Gastrointestinal Health News and Research

Synthetic Biologics' SYN-005 antibody gets FDA Orphan Drug designation for Pertussis treatment

Synthetic Biologics, Inc., a biotechnology company developing novel anti-infective biologic and drug programs targeting specific pathogens that cause serious infections and diseases, announced today that the U.S. Food and Drug Administration has granted Orphan Drug designation to the Company's proprietary SYN-005 monoclonal antibody (mAb) combination for the treatment of Pertussis, more commonly known as whooping cough.

15 Sep 2014

Postmenopausal women with diverse gut bacteria exhibit more favorable ratio of estrogen metabolites

Postmenopausal women with diverse gut bacteria exhibit a more favorable ratio of estrogen metabolites, which is associated with reduced risk for breast cancer, compared to women with less microbial variation, according to a new study published in the Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM).

12 Sep 2014

FDA approves Contrave extended-release tablets for chronic weight management

Takeda Pharmaceuticals U.S.A., Inc. and Orexigen® Therapeutics, Inc. jointly announced today that the U.S. Food and Drug Administration has approved Contrave® extended-release tablets as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition.

11 Sep 2014

Breast milk may protect premature infants from intestinal destruction

Premature infants are at increased risk for a potentially lethal gastrointestinal disease called necrotizing enterocolitis, or NEC.

9 Sep 2014

Restarting infliximab therapy after drug holiday is safe for patients with IBD

Restarting infliximab therapy after a drug holiday is safe and effective for patients with inflammatory bowel disease (IBD), according to a new study1 in Clinical Gastroenterology and Hepatology, the official clinical practice journal of the American Gastroenterological Association.

8 Sep 2014

Researchers discover genetic factors involved in development of early-onset ulcerative colitis

UCLA researchers were part of a team that has discovered the interplay of several genetic factors that may be involved in the development of early-onset ulcerative colitis, a severe type of inflammatory bowel disease.

4 Sep 2014

Around 9.6% of women diagnosed with dry eye disease, treated with artificial tear eye drops

The symptoms of dry eye disease include the sensation of grit in the eye, frequently accompanied by itching, burning and visual disturbance. The causes are poorly understood.

3 Sep 2014

Synthetic announces positive results from final preclinical toxicology study of SYN-004

Synthetic Biologics, Inc., a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today positive results from its final preclinical toxicology study of SYN-004.

2 Sep 2014

Concordia's subsidiary signs collaboration deal with Orphan Canada for PHOTOFRIN

Concordia Healthcare Corp., a diverse healthcare company focused on legacy pharmaceutical products, orphan drugs, and medical devices for the diabetic population, today announced that its subsidiary, Pinnacle Biologics, Inc., a biopharmaceutical research and development company specializing in rare diseases, has signed a collaboration agreement for PHOTOFRIN® with Orphan Canada, a Toronto-based specialty pharmaceutical company that in‐licenses therapies for rare disorders and specialty medicines within Canada.

2 Sep 2014

Study: One in every 200 Ontarians diagnosed with inflammatory bowel disease

One in every 200 Ontarians has been diagnosed with inflammatory bowel disease (IBD), with the number of people living with the disease increasing by 64 per cent between 1999 and 2008, according to a study by researchers at the Institute for Clinical Evaluative Sciences, the Children's Hospital of Eastern Ontario, and the Ottawa Hospital Research Institute.

29 Aug 2014

Irinotecan-based therapy improves survival rates for patients with stage III colon cancer

A subset of patients with stage III colon cancer had improved survival rates when treated with irinotecan-based therapy, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association.

29 Aug 2014

Genetic changes in patients with Crohn's disease could hold clues to fighting illness

Genetic changes that occur in patients with the bowel condition Crohn's disease could hold clues to fighting the illness.

27 Aug 2014

Actavis files ANDA for generic version of Neupro

Actavis plc today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Rotigotine Extended-release Transdermal Film, 1 mg/24 hr, 2mg/24 hr, 3 mg/24hr, 4 mg/24 hr, 6mg/24hr, and 8 mg/24 hr.

25 Aug 2014

Study finds a host of new clues on gene-environment interactions in Crohn's disease

A new study finds a wide range of epigenetic changes-alterations in DNA across the genome that may be related to key environmental exposures-in children with Crohn's disease (CD), reports Inflammatory Bowel Diseases, official journal of the Crohn's & Colitis Foundation of America.

23 Aug 2014

Painkillers may not offer relief to people suffering from irritable bowel syndrome

University of Adelaide researchers have discovered that the immune system is defective in people suffering from irritable bowel syndrome, which is a major reason why sufferers have ongoing issues with pain.

21 Aug 2014

Actavis reports positive results from ceftazidime-avibactam Phase III studies in cIAI patients

Actavis plc today confirmed positive topline results from RECLAIM-1 and -2, pivotal Phase III studies evaluating the potential for the investigational antibiotic, ceftazidime-avibactam as a treatment for adult hospitalized patients with complicated intra-abdominal infections.

19 Aug 2014

Microbes influence human eating behavior, dietary choices

It sounds like science fiction, but it seems that bacteria within us — which outnumber our own cells about 100-fold — may very well be affecting both our cravings and moods to get us to eat what they want, and often are driving us toward obesity.

17 Aug 2014

Research roundup: Benefits of smaller practices; Rx price growth; fixing Medicare claims reviews

The Centers for Medicare & Medicaid Services within the Department of Health and Human Services has taken steps to prevent its contractors from conducting certain duplicative postpayment claims reviews-;reviews of the same claims that are not permitted by the agency-;but CMS neither has reliable data nor provides sufficient oversight and guidance to measure and fully prevent duplication.

16 Aug 2014

Findings may lead to better ways for preventing gum disease, diabetes and Crohn's disease

Bacteria inside your mouth drastically change how they act when you're diseased, according to research using supercomputers at the Texas Advanced Computing Center.

13 Aug 2014

Synthetic Biologics hosts Investor Day to discuss irritable bowel syndrome program

Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today that it will host an Investor Day in New York to discuss the Company's irritable bowel syndrome (IBS) program, including its novel, oral product SYN-010, targeting constipation-predominant IBS (C-IBS).

13 Aug 2014

Gastrointestinal Health News and Research

Latest Gastrointestinal Health News and Research

Synthetic Biologics' SYN-005 antibody gets FDA Orphan Drug designation for Pertussis treatment

Postmenopausal women with diverse gut bacteria exhibit more favorable ratio of estrogen metabolites

FDA approves Contrave extended-release tablets for chronic weight management

Breast milk may protect premature infants from intestinal destruction

Restarting infliximab therapy after drug holiday is safe for patients with IBD

Researchers discover genetic factors involved in development of early-onset ulcerative colitis

Around 9.6% of women diagnosed with dry eye disease, treated with artificial tear eye drops

Synthetic announces positive results from final preclinical toxicology study of SYN-004

Concordia's subsidiary signs collaboration deal with Orphan Canada for PHOTOFRIN

Study: One in every 200 Ontarians diagnosed with inflammatory bowel disease

Irinotecan-based therapy improves survival rates for patients with stage III colon cancer

Genetic changes in patients with Crohn's disease could hold clues to fighting illness

Actavis files ANDA for generic version of Neupro

Study finds a host of new clues on gene-environment interactions in Crohn's disease

Painkillers may not offer relief to people suffering from irritable bowel syndrome

Actavis reports positive results from ceftazidime-avibactam Phase III studies in cIAI patients

Microbes influence human eating behavior, dietary choices

Research roundup: Benefits of smaller practices; Rx price growth; fixing Medicare claims reviews

Findings may lead to better ways for preventing gum disease, diabetes and Crohn's disease

Synthetic Biologics hosts Investor Day to discuss irritable bowel syndrome program

Microbiology eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Gastrointestinal Health News and Research

Latest Gastrointestinal Health News and Research

Microbiology eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in